drugset / Trial / NCT00424567

Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures.

NCT00424567 ↗

Phase 1/2 Terminated 36 enrolled Vericel Corporation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this multi-center study is to obtain clinical data to substantiate that Aastrom TRC autologous bone marrow cells will regenerate bone in patients with established (appendicular skeletal) non union fractures, when used with one of the commonly employed commercially available allograft chip matrices.

Timeline

Start
2003-10
Primary completion
—
Completion
2007-06

Outcome

Outcome not reported

Stopped (Business): “Closed early for business reasons (not safety reasons)”

Drugs

EvaluationDrugModalityDoseRoute
Subject Aastrom Tissue Repair Cells Cell therapy — Other

Indications